Relay Therapeutics 3Q 2026: Revenue $0 Net loss $81.7M, EPS $(0.37) — 10-Q Summary

What happened

Relay Therapeutics reported third-quarter 2026 revenue of $0 and a net loss of $81.7 million, compared with a $74.1 million loss a year earlier. Diluted loss per share was $0.37, narrower than $0.43 in the prior-year quarter. Its ReDiscover-2 Phase 3 trial is testing zovegalisib plus fulvestrant against another combination.

Confirmed

Global impact / market context

With no revenue and a larger quarterly net loss, Relay must fund its research and clinical trials without sales covering those costs. Continued spending can reduce cash available, while trial progress and regulatory outcomes could eventually create a path to revenue; the article gives no cash balance or funding outlook.

Analyst inference

The report combines worsening total losses with a narrower loss per share, so neither measure alone captures the full picture. Investors may weigh trial progress and the FDA designation against the lack of current revenue, while recognizing that approval or commercial returns from other programs are not established here.

Analyst inference

What to watch

1. Watch for further ReDiscover-2 trial updates, including progress and results: evidence of benefit could strengthen the program’s prospects, while setbacks could weaken its case for future sales. Analyst inference
2. Track upcoming financial reports for revenue, losses, and cash available; these figures would show whether research spending is increasing funding needs or whether sales are beginning. Analyst inference
3. The article says the FDA granted Breakthrough Therapy designation to zovegalisib plus fulvestrant for eligible patients with PIK3CA-mutated advanced breast cancer; this is not an approval. Confirmed

Evidence

• Original source link unavailable